UBS Maintains Buy on ALX Oncology Holdings, Lowers Price Target to $27
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Colin Bristow maintains a Buy rating on ALX Oncology Holdings (NASDAQ:ALXO) but has lowered the price target from $29 to $27.
October 04, 2023 | 3:57 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
UBS analyst Colin Bristow maintains a Buy rating on ALX Oncology Holdings but has lowered the price target from $29 to $27.
The news is directly related to ALX Oncology Holdings. The maintained Buy rating indicates a positive outlook for the company, however, the lowered price target might indicate a slightly less optimistic view on the company's short-term performance. This could potentially lead to a neutral impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100